Curetis Overview

  • Founded
  • 2007

Founded
  • Status
  • Out of Business

  • Employees
  • 79

Employees
  • Latest Deal Type
  • Liquidation

  • Financing Rounds
  • 11

  • Investments
  • 3

Curetis General Information

Description

Curetis NV is a commercial-stage molecular diagnostics company focused on rapid infectious disease testing for hospitalized patients. The company has developed Unyvero molecular diagnostic solution for comprehensive infectious disease testing.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Former Stock Listing
CUREA
Primary Office
  • Max-Eyth-Straße 42
  • 71088 Holzgerlingen
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Curetis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Curetis‘s full profile, request access.

Request a free trial

Curetis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Curetis NV is a commercial-stage molecular diagnostics company focused on rapid infectious disease testing for hospitali
Diagnostic Equipment
Holzgerlingen, Germany
79 As of 2019
00000
000000000000

000000

ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000 000000000
Seoul, South Korea
000 As of 0000
000.00
0000 0000-00-00
00000000 000.00

00 000

usmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000 000000000
Lexington, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Curetis Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
QuantaMatrix Formerly VC-backed Seoul, South Korea 000 000.00 00000000 000.00
00 0000000000 Formerly VC-backed Lexington, MA 000 00000 00000000000 00000
000000000000 Private Equity-Backed Puteaux, France 000 000.00 000000000000
0000000000 0000000 Corporation Tucson, AZ 000 000.00 0000000000 000.00
000000000 Formerly VC-backed Mechelen, Belgium 000 00000 000000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Curetis Patents

Curetis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3216873-A1 Combination of structural variations and single nucleotide changes in one statistical model for improved therapy selection Pending 08-Mar-2016 0000000000 0
AU-2016299328-A1 Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents Abandoned 29-Jul-2015 000000000
CA-2991671-A1 Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents Pending 29-Jul-2015 000000000
EP-3329009-A1 Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents Withdrawn 29-Jul-2015 000000000
US-20180216167-A1 Genetic testing for predicting resistance of stenotrophomonas species against antimicrobial agents Abandoned 29-Jul-2015 C12Q1/689 00
To view Curetis’s complete patent history, request access »

Curetis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Curetis Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 0000 13-Dec-2016 000000000 00.000 Buildings and Property 000000 00
0000 00000000 07-Sep-2016 000000000 Buildings and Property 000000 00
Ares Genetics Seed Round Other Pharmaceuticals and Biotechnology
To view Curetis’s complete investments history, request access »